Author: Pure MHC LLC
-
Myrio Therapeutics and Pure MHC, LLC Announce Research Collaboration to Develop Novel, Targeted Antibody-Based Cancer Therapies
OKLAHOMA CITY, Okla. — Pure MHC, LLC and Myrio Therapeutics Pty Ltd (Myrio) today announced a collaboration to develop new antibody-based oncology therapeutics. The companies will combine Pure MHC’s proprietary offering of MHC peptide targets for oncology with Myrio’s revolutionary Retained Display(tm) (ReD) antibody discovery process to initially create up to three novel therapies based…
-
Pure MHC, LLC Announces Launch of Contract Research Service Division and Initial Collaboration Project with argenx
AUSTIN, Texas — Pure MHC, LLC, a target discovery and development company, today announced the launch of its contract research services arm, Pure MHC Solutions, and an initial collaboration project with global immunology company, argenx.
-
Pure MHC, LLC Announces Launch of its Peptide HLA Immunotherapy Data Resource following Collaboration with LifeNet Health
AUSTIN, Texas — Pure MHC, LLC, a target discovery and development company, today announced the launch of its Peptide HLA Immunotherapy Data Resource (“PHIDR”), built through its collaboration with a trusted provider of transplant solutions and a leader in regenerative medicine, LifeNet Health.